Nektar Therapeutics (NKTR)

[seppi08162]

Do we expect the buyout before or after June? Over or under $200/share? Interested in everyone's thoughts.

Thanks,

[tigerpac]

Thanks but I think you posted the wrong presentation.

Here is the correct one:

http://files.shareholder.com/downloads/NKTR/5852742568x0x968306/0CF92912-858E-40D4-B317-46DD676BC348/NKTR-JPMorgan_2018.pdf

[tigerpac]

First significant gap and crap this morning. The spinning top of the candlestick is there for all to see. Question remains for today is if all the buying yesterday was blow off short covering with some presentation buying or if the selling today is just profit taking by some of the funds that were here in the $20-30's.

Would expect to see some analyst price target upgrades here in the next few days. Me thinks that $74 is the short term high for the next few months.

[tigerpac]

NKTR +20% .Must be some good stuff being said

President and Chief Executive Officer, Howard W. Robin, will make a presentation at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2018, at 11:00 a.m. Pacific Time

[avinanyc]

Opnt

[tigerpac]

The march higher continues as funds keep pouring money into the stock.

[tigerpac]

The head fake close yesterday under 50 was the set up for today big move. You didn't think all those big funds who bought the last few weeks over 50 were going to let this stock go down.

[tigerpac]

If the cancer drugs are really as good as the test results are showing, this stock could be a 5-10 bagger from these levels. Company would probably get bought out first imo.

[TREND1]

Float = 88.71M

[TREND1]

Earnings Per Share (EPS)= -1.10

[TREND1]

Profit/Loss = $ -153.52M

[TREND1]

NKTR CCI 10 STO 5,1

[tigerpac]

Watch the money flow. Big boys still piling in. That cancer drug must be something special.

[Maxgambit]

$NKTR breaks under 45 maybe we start our first down in a while

[starkd748]

Yessss sir

[tigerpac]

Every dip is being bought hard. Institutional buying.

[tigerpac]

The two Form 4's filed here shows that the SVP's couldn't wait exercise and sell their shares. Earnings came out after market on 11/7/17 yet they were selling on 11/6, 11/7, and 11/8. Thought there was a blackout period where insiders couldn't sell shares within 5 days of earnings.

They turned out to be wrong as well as the stock took off and they lost potential profits.

[starkd748]

Lol Abe been here no brainer

[tigerpac]

Finally this stock has broken out of it's base...owned it a long time ....since the Afrezza days.....

[starkd748]

Booooooooom im back on it.....

[starkd748]

Booooooom im back on it.

[starkd748]

Up she goed

[starkd748]

Nice trafding 30$ soon...

[starkd748]

This one is a keeper starkd

[starkd748]

Glad I put 11k in here yeehaw...nice hedge with my mmj plays

[jones99]

These analysts upgrading to the sky only for them to support a secondary at 1/4 of price..typical bio pump after any level of success

[biotechnician]

$75+

[blackcat]

Nektar Therapeutics
Mar 20, 2017

NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain
NKTR-181 Significantly Reduced Pain in Patients with Moderate to Severe Chronic Low Back Pain
Primary Efficacy Endpoint Achieved (p=0.0019)
Analyst Conference Call and Webcast Today at 5:45 a.m. PDT/8:45 a.m. EDT

SAN FRANCISCO, March 20, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.1 The U.S. Food and Drug Administration (FDA) has granted the investigational medicine NKTR-181 Fast Track designation for the treatment of moderate to severe chronic pain.

"The data from this efficacy study are extremely important because they demonstrate that NKTR-181 produces strong analgesia in patients suffering from chronic pain while NKTR-181 has also demonstrated significantly lower abuse potential than oxycodone in a human abuse potential study," said clinical investigator Martin Hale, M.D., medical director of Gold Coast Research. "While standard opioid analgesics, including abuse-deterrent formulations, have been the most effective way to treat chronic pain, they are associated with serious safety concerns and many opioid-naïve patients fear taking them because of the potential for abuse and addiction. The data for NKTR-181 suggest that it is a transformational pain medicine that could fundamentally change how we treat patients with chronic pain conditions."

The SUMMIT-07 study compared twice-daily dosing of NKTR-181 tablets to placebo in the treatment of over 600 patients with moderate to severe chronic low back pain who were new to opioid therapy (opioid-naïve). The clinical trial met the primary efficacy endpoint of the study in demonstrating significantly improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Key secondary endpoints of the study were also met with high statistical significance.

Pain is one of the most common reasons people seek medical treatment.2 Low back pain is the second most common cause of disability for adults in the U.S. 3 Approximately 149 million work days are lost every year because of low back pain, with total costs estimated to be $100 to 200 billion a year (of which two-thirds is due to lost wages and lower productivity).4 A study published in the American Pain Society's The Journal of Pain in October 2014 estimated that 19 percent of the U.S. population, or 39 million people, suffer from some type of persistent pain.5

The Phase 3 SUMMIT-07 study used an enriched-enrollment randomized withdrawal (EERW) trial design in patients with moderate to severe chronic low back pain. The trial included an open-label titration period in which patients were titrated to a tolerated, effective dose of NKTR-181 (100 mg to 400 mg twice-daily). Following this open-label titration period, patients entered a double-blind, placebo-controlled treatment period in which they were randomized 1:1 to either continue to receive the tolerated, effective dose of NKTR-181 or to receive matching placebo (i.e. active drug was withdrawn) for a period of 12 weeks.

During the open-label titration period of the trial in which patients were titrated to a tolerated, effective dose of NKTR-181, average pain scores dropped by 65% (from 6.73 at screening to 2.32 at randomization, n=610).

The primary endpoint of the study was mean change in the weekly average pain score in the double-blind randomized treatment period from baseline (end of open-label titration period) to week 12 (end of double-blind randomized treatment period).

Primary and key sensitivity analyses:

During the double-blind randomized treatment period of the trial, average pain scores increased more in the placebo arm versus NKTR-181 at week 12 from randomization baseline (1.46, placebo versus 0.92, NKTR-181, p=0.0019, n=610).
83% of patients completed the 12-week double-blind randomized treatment period and for these study completers, average pain scores increased more in the placebo arm versus NKTR-181 at week 12 from baseline (1.25, placebo versus 0.56, NKTR-181, p < 0.0001, n=504).

Key secondary endpoints:

A statistically significant proportion of patients on NKTR-181 experienced pain reductions greater than 30% compared to placebo (71.2% versus 57.1%; p=0.0003).
A statistically significant proportion of patients on NKTR-181 experienced pain reductions greater than 50% compared to placebo (51.1% versus 37.9%; p=0.001).
A statistically significant proportion of patients on NKTR-181 reported their general overall status and quality of life as "improved" or "very much improved" compared to placebo as assessed by the Patient's Global Impression of Change (PGIC) of pain medication questionnaire (51.5% versus 33.2%; p < 0.0001).

The study also demonstrated that NKTR-181 had a favorable safety profile and was well tolerated. During the double-blind randomized treatment period, the most commonly reported adverse events for patients ( > 5%) were nausea (10.4%) and constipation (8.7%) in the NKTR-181 arm as compared to nausea (6.0%) and constipation (3.0%) in the placebo arm.

Patients randomized to NKTR-181 as compared to placebo reported more favorable sleep outcomes as measured by the validated Medical Outcomes Study (MOS) Sleep Scale, which captures debilitating aspects of sleep most strongly associated with chronic pain. Patients reported better overall quality of sleep with less sleep problems on NKTR-181 versus placebo. There were no differences in daytime sleepiness on NKTR-181 versus placebo.

Full data from the SUMMIT-07 study will be presented at a medical meeting in the second half of 2017.

"As a new molecule, NKTR-181 has a highly differentiated profile with the potential to be one of the most important advancements in pain medicine," said Howard W. Robin, President and CEO of Nektar Therapeutics. "Given the seriousness of the current opioid epidemic in the U.S. and the significant number of people battling chronic pain, we are committed to bringing this new molecule to patients and physicians as quickly as possible."

In March 2017, results from a separate human abuse potential trial of NKTR-181 were published in the American Academy of Pain Medicine's journal of Pain Medicine. The human abuse potential study assessed the relative abuse potential of a range of therapeutic doses of NKTR-181 (100 mg to 400 mg), the same dose range evaluated in the Phase 3 SUMMIT-07 efficacy trial. All doses of NKTR-181 tested for abuse potential were rated similarly to placebo in "drug liking" and "feeling high" scores and had highly statistically significant lower "drug liking" scores and reduced "feeling high" scores as compared to 40 mg oxycodone (p < 0.0001). In addition, all doses of NKTR-181 also scored lower on sleepiness when compared to 40 mg oxycodone (p < 0.0001).

"It is clear that there is a pressing societal need for better and safer analgesics," said Dr. Jack Henningfield, Ph.D., Adjunct Professor of Behavioral Biology in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine and Head of Health Policy and Abuse Liability at Pinney & Associates in Bethesda, MD. "In the human abuse potential study, even the highest analgesic dose of NKTR-181 was barely distinguishable from placebo with respect to both drug-liking and feeling high and these effects were modest compared to those produced by oxycodone. Drug-liking and feeling high are two of the most important metrics that help us understand the abuse potential of a medicine. Importantly, as NKTR-181 is a new chemical entity, the properties of NKTR-181 are inherent to its molecular structure and independent of any abuse-deterrent formulation. Today's reported efficacy and safety results, along with the human abuse potential data published this past week in Pain Medicine, suggest NKTR-181 may be a major advance towards safer opioid therapy for the treatment of moderate to severe chronic pain."

[TERIA]

New updates on NKTR-181 - the novel opioid for chronic pain, presented by Stephen Doberstein , Senior Vice President and Chief Scientific Officer from Nektar Therapeutics. More information on the talk at the 17th Annual Pain Therapeutics summit in London are available at http://www.pain-therapeutics.co.uk/ihub

[DrShocker]

Love this stock

[TERIA]

Strategy on opioid abuse
Stephen Doberstein Senior Vice President and Chief Scientific Officer from Nektar Therapeutics will be chairing the 16th annual Pain Therapeutics conference in May! Engineering brain entry rate to reduce opioid abuse indicating that Nektar are on the cusp of some major developments in Pain drugs. Pain Therapeutics

[TERIA]

[DrShocker]

Moving in the right direction atleast

[DrShocker]

12+ close

[stocktrademan]

$NKTR recent news/filings

bullish 15.85

## source: finance.yahoo.com

Thu, 03 Dec 2015 16:04:18 GMT ~ Nektar Therapeutics Earnings Q3, 2015


read full: http://www.capitalcube.com/blog/index.php/nektar-therapeutics-earnings-q3-2015/
*********************************************************

Mon, 30 Nov 2015 15:21:00 GMT ~ Baxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients with Hemophilia A With a Simple, Twice-Weekly Dosing Schedule

[PR Newswire] - BANNOCKBURN, Ill., Nov. 30, 2015 /PRNewswire/ -- Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and ...

read full: http://finance.yahoo.com/news/baxalta-announces-u-availability-adynovate-152100847.html
*********************************************************

Wed, 25 Nov 2015 13:16:34 GMT ~ Hedge Funds Aren’t Crazy About Nektar Therapeutics (NKTR) Anymore


read full: http://www.insidermonkey.com/blog/hedge-funds-arent-crazy-about-nektar-therapeutics-nktr-anymore-388609/
*********************************************************

Tue, 17 Nov 2015 21:31:00 GMT ~ Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out


read full: http://www.thestreet.com/story/13369571/1/get-ready-for-nektar-nktr-stock-to-break-out.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Tue, 17 Nov 2015 21:01:00 GMT ~ Why Nektar Therapeutics Skyrocketed 30% Higher in October


read full: http://www.fool.com/investing/general/2015/11/17/why-nektar-therapeutics-skyrocketed-30-higher-in-o.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article
*********************************************************

$NKTR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$NKTR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NKTR/company-info
Ticker: $NKTR
OTC Market Place: Not Available
CIK code: 0000906709
Company name: Nektar Therapeutics
Company website: http://www.nektar.com
Incorporated In: DE, USA

$NKTR share structure

## source: otcmarkets.com

Market Value: $2,029,795,368 a/o Dec 03, 2015
Shares Outstanding: 133,451,372 a/o Oct 29, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$NKTR extra dd links

Company name: Nektar Therapeutics
Company website: http://www.nektar.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NKTR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NKTR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NKTR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/news - http://finance.yahoo.com/q/h?s=NKTR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NKTR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NKTR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NKTR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nektar+Therapeutics&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nektar+Therapeutics
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nektar+Therapeutics&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nektar.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nektar.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nektar.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NKTR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000906709&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NKTR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NKTR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NKTR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NKTR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NKTR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NKTR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NKTR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NKTR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NKTR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NKTR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NKTR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NKTR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NKTR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NKTR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NKTR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NKTR



$NKTR DD Notes ~ http://www.ddnotesmaker.com/NKTR

[stocktrademan]

$NKTR recent news/filings

bullish 13.43
'golden cross' moving average pattern

## source: finance.yahoo.com

Fri, 13 Nov 2015 18:04:26 GMT ~ NEKTAR THERAPEUTICS Financials


read full: http://finance.yahoo.com/q/is?s=nktr
*********************************************************

Sat, 07 Nov 2015 13:46:40 GMT ~ Edited Transcript of NKTR earnings conference call or presentation 5-Nov-15 10:00pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-nktr-earnings-conference-134640704.html
*********************************************************

Fri, 06 Nov 2015 15:08:03 GMT ~ Nektar (NKTR) Reports Narrower-than-Expected Q3 Loss


read full: http://finance.yahoo.com/news/nektar-nktr-reports-narrower-expected-150803275.html
*********************************************************

Fri, 06 Nov 2015 12:58:49 GMT ~ NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/151106/nktr10-q.html
*********************************************************

Thu, 05 Nov 2015 22:00:00 GMT ~ Nektar Therapeutics Earnings Call scheduled for 5:00 pm ET today


read full: http://biz.yahoo.com/cc/1/148641.html
*********************************************************

$NKTR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$NKTR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NKTR/company-info
Ticker: $NKTR
OTC Market Place: Not Available
CIK code: 0000906709
Company name: Nektar Therapeutics
Company website: http://www.nektar.com
Incorporated In: DE, USA


$NKTR share structure

## source: otcmarkets.com

Market Value: $1,792,251,926 a/o Nov 13, 2015
Shares Outstanding: 133,451,372 a/o Oct 29, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$NKTR extra dd links

Company name: Nektar Therapeutics
Company website: http://www.nektar.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NKTR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NKTR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NKTR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/news - http://finance.yahoo.com/q/h?s=NKTR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NKTR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NKTR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NKTR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nektar+Therapeutics&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nektar+Therapeutics
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nektar+Therapeutics&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nektar.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nektar.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nektar.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NKTR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000906709&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NKTR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NKTR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NKTR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NKTR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NKTR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NKTR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NKTR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NKTR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NKTR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NKTR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NKTR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NKTR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NKTR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NKTR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NKTR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NKTR



$NKTR DD Notes ~ http://www.ddnotesmaker.com/NKTR

[stocktrademan]

$NKTR recent news/filings

bullish
long term


http://ir.nektar.com/

## source: finance.yahoo.com

Thu, 10 Sep 2015 11:03:00 GMT ~ Nektar Therapeutics' Stock Slumped in August; Here's Why


read full: http://www.fool.com/investing/general/2015/09/10/nektar-therapeutics-stock-slumped-in-august-heres.aspx?source=eogyholnk0000001
*********************************************************

Thu, 03 Sep 2015 13:40:01 GMT ~ Nektar Receives $40M Milestone Payment from AstraZeneca


read full: http://finance.yahoo.com/news/nektar-receives-40m-milestone-payment-134001433.html
*********************************************************

Tue, 01 Sep 2015 12:30:00 GMT ~ Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market

[PR Newswire] - SAN FRANCISCO, Sept. 1, 2015 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany. MOVENTIG is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication approved in the European Union for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MOVENTIG is marketed in the U.S. by AstraZeneca as MOVANTIK™ (naloxegol) and is the first once-daily oral PAMORA medication indicated for the treatment of OIC in adult patients with chronic, non-cancer pain.

read full: http://finance.yahoo.com/news/nektar-announces-receipt-40-million-123000224.html
*********************************************************

Fri, 14 Aug 2015 17:04:09 GMT ~ NEKTAR THERAPEUTICS Financials


read full: http://finance.yahoo.com/q/is?s=nktr
*********************************************************

Mon, 10 Aug 2015 00:13:03 GMT ~ 10-Q for Nektar Therapeutics


read full: http://www.companyspotlight.com/routers/headline/23261/10004/6551558?cp_code=YAH1&1439165583
*********************************************************

$NKTR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$NKTR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NKTR/company-info
Ticker: $NKTR
OTC Market Place: Not Available
CIK code: 0000906709
Company name: Nektar Therapeutics
Company website: http://www.nektar.com
Incorporated In: DE, USA

$NKTR share structure

## source: otcmarkets.com

Market Value: $1,620,221,040 a/o Sep 11, 2015
Shares Outstanding: 132,371,000 a/o Jul 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$NKTR extra dd links

Company name: Nektar Therapeutics
Company website: http://www.nektar.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NKTR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NKTR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NKTR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/news - http://finance.yahoo.com/q/h?s=NKTR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NKTR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NKTR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NKTR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nektar+Therapeutics&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nektar+Therapeutics
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nektar+Therapeutics&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nektar.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nektar.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nektar.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NKTR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000906709&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NKTR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NKTR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NKTR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NKTR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NKTR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NKTR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NKTR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NKTR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NKTR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NKTR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NKTR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NKTR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NKTR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NKTR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NKTR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NKTR



$NKTR DD Notes ~ http://www.ddnotesmaker.com/NKTR

[TREND1]

NKTR 30 D W M PF

[TREND1]

Inst % Owned = 95%

[TREND1]

FLOAT = 87.75

[TREND1]

EPS= .07

[TREND1]

NKTR PF

[blackcat]

S&P index changes: ATI, CASY, ENR UNT, SMTC, NKTR, GCI, PGN

Also joining the S&P SmallCap 600: Nektar (NASDAQ:NKTR)

[stocktrademan]

$NKTR DD Notes ~ http://www.ddnotesmaker.com/NKTR

bullish

$NKTR recent news/filings

## source: finance.yahoo.com

Wed, 03 Dec 2014 16:57:00 GMT ~ Biotech: When and Where to Sell


read full: http://www.forbes.com/sites/tomaspray/2014/12/03/biotech-when-and-where-to-sell/?partner=yahootix
*********************************************************

Mon, 01 Dec 2014 14:18:00 GMT ~ Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A

[PR Newswire] - SAN FRANCISCO, Dec. 1, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application ...

read full: http://finance.yahoo.com/news/baxter-submits-application-us-fda-141800350.html
*********************************************************

Mon, 01 Dec 2014 10:36:59 GMT ~ Nektar Therapeutics (NKTR): Strong Industry, Solid Earnings Estimate Revisions


read full: http://finance.yahoo.com/news/nektar-therapeutics-nktr-strong-industry-103659420.html
*********************************************************

Wed, 26 Nov 2014 12:34:13 GMT ~ Will Nektar Therapeutics (NKTR) Continue to Surge Higher?


read full: http://finance.yahoo.com/news/nektar-therapeutics-nktr-continue-surge-123413446.html
*********************************************************

Mon, 24 Nov 2014 15:12:00 GMT ~ FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation

[PR Newswire] - WHIPPANY, N.J., Nov. 24, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin ...

read full: http://finance.yahoo.com/news/fda-grants-qidp-designation-bayers-151200312.html
*********************************************************


$NKTR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$NKTR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NKTR/company-info
Ticker: $NKTR
OTC Market Place: Not Available
CIK code: 0000906709
Company name: Nektar Therapeutics
Company website: http://www.nektar.com
Incorporated In: DE, USA


$NKTR share structure

## source: otcmarkets.com

Market Value: $2,049,924,840 a/o Dec 04, 2014
Shares Outstanding: 128,441,406 a/o Oct 30, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$NKTR extra dd links

Company name: Nektar Therapeutics
Company website: http://www.nektar.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NKTR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NKTR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NKTR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/news - http://finance.yahoo.com/q/h?s=NKTR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NKTR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NKTR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NKTR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nektar+Therapeutics&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nektar+Therapeutics
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nektar+Therapeutics&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nektar.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nektar.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nektar.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NKTR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000906709&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NKTR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NKTR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NKTR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NKTR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NKTR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NKTR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NKTR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NKTR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NKTR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NKTR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NKTR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NKTR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NKTR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NKTR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NKTR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NKTR



$NKTR DD Notes ~ http://www.ddnotesmaker.com/NKTR

[maytepper]

$NKTR Roth Capital Reiterates Buy On Nektar Therapeutics Following BAX-855 BLA Submission http://www.smarteranalyst.com/2014/12/02/roth-capital-reiterates-buy-on-nektar-therapeutics-following-bax-855-bla-submission/

[ClayTrader]

* * $NKTR Video Chart 9-16-14 * *

Link to Video - click here to watch the technical chart video

[maytepper]

$NKTR Nektar: Movantik Approval Unlocks Significant Economic Value for Nektar, Says William Blair http://www.smarteranalyst.com/2014/09/16/nektar-movantik-approval-unlocks-significant-economic-value-for-nektar-says-william-blair/

[Ratan09]

That is correct, guess I am still sleepy, thanks for the correction.

[$$$eeker]

$NKTR is having a PDUFA on 9/16

[Ratan09]

PDUFA for MOVANTIK on Sept 16th